Comprehensive molecular profiling of lung adenocarcinoma
Eric Andrew Collisson, Barry S. Taylor, Joshua David Campbell et al. · Nature · 2014
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Cited by 5,703 works. doi:10.1038/nature13385 Open-access PDF
Authors
- Eric Andrew Collisson
- Barry S. Taylor
- Joshua David Campbell
- Angela N. Brooks
- Alice H. Berger
- Juliann Chmielecki
- Gad A. Getz
- Peter S. Hammerman
- BRYAN HERNANDEZ
- Carrie L. Sougnez
- Andrew D. Cherniack
- Mara W. Rosenberg
- Matthew M. Meyerson
- Stacey L. Gabriel
- Kristian Cibulskis
- Jaegil Kim
- Chip Stewart
- Eric S. Lander
- Michael S. Lawrence
References
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- Somatic mutations affect key pathways in lung adenocarcinoma
- Comprehensive genomic characterization of squamous cell lung cancers
- Gene-expression profiles predict survival of patients with lung adenocarcinoma